Diabetic Retinopathy Market : Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Diabetic Retinopathy Market by Type (Proliferative DR and Diabetic Macular Edema), Drug Class (Corticosteroids, Anti-VEGF (vascular endothelial growth factor)) Distribution Channels (Ophthalmic Clinics, Hospital Pharmacies, Retail pharmacies) Geography

 

 

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Diabetic Retinopathy Market size was estimated at USD 6.24 Bn in 2021, growing at a CAGR of 7.1% during the forecast period 2022-2028. Report Snapshot of Diabetic Retinopathy Market: Diabetic retinopathy is the most common form of diabetic eye disease. Diabetic retinopathy usually affects the people with diabetes from number of years. High glucose levels in the cause damage to the retinal blood vessels is the main manifestation in diabetic retinopathy. In some other cases, the retinal blood vessels will be swollen (macular oedema) with a fluid leaking into rear of eye. In few cases, on the surface of the retinal blood vessels will grow abnormally. If diabetic retinopathy market is not properly treated, can progressively become more serious and seriously affects vision which may leads to blindness. Diabetic retinopathy can be treated by various methods depending on the stage of disease. Diabetic retinopathy is one of the major causes of blindness in adult population in America. As per, World Health Organisation (WHO), 347 Mn people were suffering from diabetes globally in 2012, in which 11% population are having diabetic retinopathy. Increase in focus on Asia-pacific and LAMEA regions by various vendors is expected to boost growth of the market According to the World Bank, in 2015,10.4% of rate of  prevalence of diabetes was observed in Brazil. Strategic acquisitions, geographic expansion, agreements, partnerships and new product launches are the most vital strategic implementations by most of the companies in the market of diabetic retinopathy.

Diabetic Retinopathy Market

MARKET SUMMARY
-
7.1% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 7.1%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Diabetic Retinopathy Market

  • The report on the global Diabetic Retinopathy Market gives historical, current, and future market sizes (US$ Bn) on the basis of treatment, end users, type, and region
  • global Diabetic Retinopathy Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • In 2017, Roche got FDA approval for Lucentis ( Ranibizumab injection) for the treatment of diabetic retinopathy
  • In 2014, Regeneron Pharmaceuticals, EYLEA® (aflibercept) injection received USFDA breakthrough therapy designation for to treat diabetic retinopathy in patients with diabetic macular edema (DME)
  • In 2014, Regeneron Pharmaceuticals, EYLEA® (aflibercept) injection received European Commission to treat diabetic retinopathy in patients with diabetic macular edema (DME)
Market Key Players
  • Abbott Laboratories (U.S.)
  • Alimera Sciences (U.S.)
  • Allergan plc (Ireland.)
  • Ampio Pharmaceuticals. (U.S.)
  • Bayer AG (Germany)
  • F. Hoffmann-La Roche (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Regeneron Pharmaceuticals Inc. (U.S.)
  • Valeant (Canada)
Drivers And Restraints

Diabetic Retinopathy Market

Diabetic Retinopathy will affect both type 1 and type 2 diabetic patients and due to the abundant increase in the pool of patients with Diabetes, According to the World Health Organisation (WHO), 41 % of global population with diabetes are geriatric patients which is highly attributing the growth of the diabetic retinopathy market. Furthermore, rise in healthcare infrastructure up-gradation, rise in demand for the early diagnosis devices are the few factors having significant impact in driving the diabetic retinopathy market. However, paucity of skilled ophthalmologist, lack of primary infrastructure and insurance facilities are some of the restraining factors that are hampering the growth of diabetic retinopathy market.


North-America got significant share

Diabetic Retinopathy Market

On the basis of regions, the global market of diabetic retinopathy has been segmented into five key regions, Latin America North America, Asia-Pacific, Europe, and Middle East & Africa. North America dominates the market followed by Asia-Pacific and Europe. The factors that are attributing for the market growth in North America are, people with high obesity rates are more prone to diabetes conditions. Large patient pool in European region with diabetic retinopathy is expected to drive the growth of the market. In emerging economies, due to the improvement in the healthcare infrastructure and rise in awareness in the people Owing to improved infrastructure and awareness among the people, improving on the quality of life (QALY) in diabetic patients, rise in demand of early detection and treatment of chronic conditions such as diabetic retinopathy are the factors that are driving the growth of the diabetic retinopathy market in Asia Pacific regions.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast from 2022-2028
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Segmentation

Diabetic Retinopathy Market


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Abbott Laboratories (U.S.)
  • Alimera Sciences (U.S.)
  • Allergan plc (Ireland.)
  • Ampio Pharmaceuticals. (U.S.)
  • Bayer AG (Germany)
  • F. Hoffmann-La Roche (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Regeneron Pharmaceuticals Inc. (U.S.)
  • Valeant (Canada)

Description

Diabetic Retinopathy Market size was estimated at USD 6.24 Bn in 2021, growing at a CAGR of 7.1% during the forecast period 2022-2028. Report Snapshot of Diabetic Retinopathy Market: Diabetic retinopathy is the most common form of diabetic eye disease. Diabetic retinopathy usually affects the people with diabetes from number of years. High glucose levels in the cause damage to the retinal blood vessels is the main manifestation in diabetic retinopathy. In some other cases, the retinal blood vessels will be swollen (macular oedema) with a fluid leaking into rear of eye. In few cases, on the surface of the retinal blood vessels will grow abnormally. If diabetic retinopathy market is not properly treated, can progressively become more serious and seriously affects vision which may leads to blindness. Diabetic retinopathy can be treated by various methods depending on the stage of disease. Diabetic retinopathy is one of the major causes of blindness in adult population in America. As per, World Health Organisation (WHO), 347 Mn people were suffering from diabetes globally in 2012, in which 11% population are having diabetic retinopathy. Increase in focus on Asia-pacific and LAMEA regions by various vendors is expected to boost growth of the market According to the World Bank, in 2015,10.4% of rate of  prevalence of diabetes was observed in Brazil. Strategic acquisitions, geographic expansion, agreements, partnerships and new product launches are the most vital strategic implementations by most of the companies in the market of diabetic retinopathy.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX